Compare
Minerva Neurosciences, Inc. vs Eton Pharmaceuticals, Inc. vs Tenax Therapeutics, Inc. vs Pyxis Oncology, Inc.
| Latest fiscal year | Minerva Neurosciences, Inc. NERVRevenue covers only part of its income (partial revenue) | Eton Pharmaceuticals, Inc. ETON | Tenax Therapeutics, Inc. TENX | Pyxis Oncology, Inc. PYXS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $79.95M | $0 | $13.86M |
| Revenue growth (YoY) | n/a | +104.9% | n/a | -14.2% |
| Gross margin | n/a | 53.5% | n/a | 82.8% (computed) |
| Operating margin | n/a | -1.1% | n/a | -609.2% |
| Net margin | n/a | -5.8% | n/a | -574.5% |
| Net income | -$293.42M | -$4.60M | -$52.60M | -$79.62M |
| EPS (Diluted) | -$34.67 | n/a | -$1.34 | -$1.28 |
| Operating cash flow | -$13.51M | $10.52M | -$35.80M | -$63.50M |
| Free cash flow | n/a | $10.19M | n/a | -$63.51M |
| Cash & equivalents | $82.30M | $25.94M | $97.60M | $15.42M |
| Total assets | $97.97M | $92.11M | $104.23M | $91.52M |
| Total liabilities | $233.76M | $65.96M | $7.16M | $38.11M |
| Shareholders' equity | -$140.75M | $26.15M | $97.07M | $53.41M |
| Return on year-end equity | n/a | -17.6% | -54.2% | -149.1% |
| Shares outstanding | 43.27M | 27.05M | 9.31M | 62.69M |
Revenue, most recent five fiscal years
| Fiscal year | Minerva Neurosciences, Inc. | Eton Pharmaceuticals, Inc. | Tenax Therapeutics, Inc. | Pyxis Oncology, Inc. |
|---|---|---|---|---|
| Latest | n/a | $79.95M Ended 2025-12-31 | $0 Ended 2025-12-31 | $13.86M Ended 2025-12-31 |
| 1 year earlier | n/a | $39.01M Ended 2024-12-31 | $0 Ended 2024-12-31 | $16.15M Ended 2024-12-31 |
| 2 years earlier | n/a | $31.64M Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | n/a | $21.25M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $21.83M Ended 2021-12-31 | n/a | n/a |